In 2020, VOYAGER PAD study1 demonstrated that in lower extremity arterial disease (LEAD) patients undergoing revascularization, rivaroxaban at a dose of 2.5 mg twice daily plus aspirin was associated with a significantly lower incidence of the composite outcome of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes than aspirin alone. However, recently ESC Working Group on Aorta and Peripheral Vascular Disease in collaboration with other European scientific societies involved in chronic limb-threatening ischemia (CLTI) management published the outcomes of a worldwide web-based survey, where Dual Pathway Inhibition (DPI) with aspirin and low-dose rivaroxaban is prescribed only by 16% of respondents.2 Besides, no data exist in Literature about DPI prescription performed by a selected population including only vascular surgeons. A web-based questionnaire was designed to obtain a contemporary picture of the relationship between vascular surgeons and rivaroxaban prescription in patients with symptomatic LEAD. The survey was in English, including 16 questions (nine of them related to rivaroxaban prescription). It was designed to be completed in less than 10 minutes. All the vascular surgeons could fill the survey on Google platform (https://docs.google.com/forms/d/1dtoC83VLJixwXYQnXR8LyhEOpx2kSiTCXtHK5074Yc8/edit). A total of 254 vascular surgeons from 37 countries completed the survey. Most of the answers came from European countries (203, 79.9%). Most of the responders were male (182, 71.7%). Age of participants was <30 years in 37 cases (14.6%), 31-40 years in 96 cases (37.8%), 41-50 years in 65 cases (25.6%), 51-60 years in 38 cases (15%), and >60 years in 18 cases (7%). Years of experience were <5 years in 52 cases (20.5%), 6-10 years in 50 cases (19.7%), 11-20 years in 80 cases (31.5%), and >20 years in 72 cases (28.3%).
Troisi, N., Bertagna, G., Berchiolli, R., Abdelrahman, A., Abd Elhamid, M. S., Abdelhamid, M., Abruzzino, G., Accrocca, F., Ada-Mi, D., Aguirre, M., Ahmed, M., Al Halabi, A., Alberti, A., Albino, J., Ali, B. A., Aloisi, F., Altaf, N., Amoretti Polesso, M., Andreini, M., Angelini, A., Angiletta, D., Antignani, P. L., Antonello, M., Anzaldi, M., Apruzzi, L., Artini, V., Ascione, M., Ascoli Marchetti, A., Avgerinos, E., Bafile, G., Bahaa, N., Balestrini, J., Baraldi, C., Barbarisi, D., Barilla, C., Barre-Ras Molinelli, L., Barsim, E., Barzaghi, M. E., Battocchio, P., Battocchio, C., Behrendt, C. -., Bellmunt-Montoya, S., Berchiolli, R., Beretta, A., Bertagna, G., Bertoglio, L., Bianchini Massoni, C., Biancofiore, B., Biandolino, P., Biscetti, F., Bishara, R., Bissacco, D., Bridda, A., Briolini, F., Bucelli, S., Bugueiro Bertier, A., Cabrini, E., Cangiano, R., Canovaro, F., Capone, A., Carrasco, I. L., Casali, E., Casini, A., Cemirtan, R., Cervarolo, M. C., Chauvet, R., Cherchi, M., Chincarini, C., Chisci, E., Cia-Varelli, F., Cicala, N., Colacchio, E. C., Cooper, M., Coscas, R., Cvjetko, I., D'Amico, C., Dabravolskaite, V., Dalla Caneva, P., De Blasis, S., De Donato, G., Del Corso, A., Dias, L., D'Oria, M., Dorigo, W., Dua, A., Ebben, H. P., Eefting, D., El Semary, A., Elmayet, M. M., Ercolini, L., Esposito, G., Esposito, D., Farkas, V., Ferrante, G., Ferraresi, R., Ferreira, V., Ficarelli, I., Filippi, F., Fittipaldi, A., Forcella, E., Fornasari, A., Freyrie, A., Frigatti, P., Frosini, P., Fumagalli, M., Furlan, F., Galachev, V., Gargiulo, B., Garriboli, L., Gatta, E., Ghosh, S. K., Giacomelli, E., Giannasio, B., Giordano, A. N., Gonzalez, T. M., Gouveia E Melo, R., Gugliotta, M. C., Guidi, C., Guidotti, A., Guillermo, G., Hadi, S. A., Hamada, W. A., Hussein, E., Ibrahim, O., Ibrahim, A., Isernia, G., Janho, K. E., Jansen, S., Javed, I., Khashram, M., Khereba, W., Korosoglou, G., Kostiv, S., Kukulski, L., Kwok, R., Lasagni, C., Leo, M., Liapis, C., Lombardi, R., Longchamp, J., Loureiro, L., Loutfi, M., Malquori, V., Mansour, W., Marconi, M., Margheritini, C., Martelli, M., Martelli, E., Marzano, A., Masoni, C., Massaini, G., Matejevic, D., Med Cherif, D., Melani, A., Mele, M. A., Melloni, A., Mezzetto, L., Miceli, F., Michailidis, P., Michelagnoli, S., Mocellin, D. M., Mohamed, H. A., Molon, E., Moreira, R., Mozzetta, G., Mufty, H., Mujica, L., Narayanan, A., Nardella, E., Natola, M., Nick, S., Nikolov, N., Oddi, F. M., Oller Grau, M., Orlov, A., Orticelli, A., Osama, I., Ozdemir-Van Brunschot, D., Pacile, M. A., Panella, M., Panzano, C., Parlani, G., Patelis, N., Peinado, J., Pereira, M., Perini, P., Perkmann, R., Peruffo, M., Petrovic, L., Piffaretti, G., Pigozzi, C., Pillny, M., Pisachuk, S., Piscitello, E., Polisetti, F., Pranteda, C., Pulli, R., Quercioli, L., Raj, S. P., Ramadan, M., Ramdon, A., Rando, M. M., Reutersberg, B., Ri-Volta, N., Robinson, S., Rocha Neves, J., Rotiroti, I., Roy, J., Saab, F., Sabato, A., Saengprakai, W., Samir, A., Sanna, V., Sarker, S. R., Scali, S., Scarati, V., Sen, I., Setacci, C., Sevilla Martinez, D., Shalhoub, J., Sharma, D., Siani, A., Simonte, G., Sirignano, P., Spertino, A., Spiliopoulos, S., Squillaci, D., Stella, N., Taurino, M., Tomei, F., Torri, L., Torsello, G., Trillini, M., Troisi, N., Tundo, E., Turini, F., Ucci, A., Ugalde Pizzi, R. J., Usai, M. V., Vallesi, V., Van Den Berg, J., Van Herzeele, I., Vasudevan, T., Veraldi, G. F., Vikatmaa, P., Villani, F., Vujcic, A., Wende, A., Wiersema, A., Wijers, D., Zaraca, F., Zayed, H., Zenunaj, G., Zlatanovic, P., RIvaroxaban and Vascular Surgery (rIVaS): insights from a multicenter, worldwide web-based survey, <<INTERNATIONAL ANGIOLOGY>>, 2024; 43 (2): 306-308. [doi:10.23736/S0392-9590.24.05146-0] [https://hdl.handle.net/10807/315676]
RIvaroxaban and Vascular Surgery (rIVaS): insights from a multicenter, worldwide web-based survey
Biscetti, FedericoMembro del Collaboration Group
;Nardella, Elisabetta;Natola, Marco;Rando, Maria Margherita;
2024
Abstract
In 2020, VOYAGER PAD study1 demonstrated that in lower extremity arterial disease (LEAD) patients undergoing revascularization, rivaroxaban at a dose of 2.5 mg twice daily plus aspirin was associated with a significantly lower incidence of the composite outcome of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes than aspirin alone. However, recently ESC Working Group on Aorta and Peripheral Vascular Disease in collaboration with other European scientific societies involved in chronic limb-threatening ischemia (CLTI) management published the outcomes of a worldwide web-based survey, where Dual Pathway Inhibition (DPI) with aspirin and low-dose rivaroxaban is prescribed only by 16% of respondents.2 Besides, no data exist in Literature about DPI prescription performed by a selected population including only vascular surgeons. A web-based questionnaire was designed to obtain a contemporary picture of the relationship between vascular surgeons and rivaroxaban prescription in patients with symptomatic LEAD. The survey was in English, including 16 questions (nine of them related to rivaroxaban prescription). It was designed to be completed in less than 10 minutes. All the vascular surgeons could fill the survey on Google platform (https://docs.google.com/forms/d/1dtoC83VLJixwXYQnXR8LyhEOpx2kSiTCXtHK5074Yc8/edit). A total of 254 vascular surgeons from 37 countries completed the survey. Most of the answers came from European countries (203, 79.9%). Most of the responders were male (182, 71.7%). Age of participants was <30 years in 37 cases (14.6%), 31-40 years in 96 cases (37.8%), 41-50 years in 65 cases (25.6%), 51-60 years in 38 cases (15%), and >60 years in 18 cases (7%). Years of experience were <5 years in 52 cases (20.5%), 6-10 years in 50 cases (19.7%), 11-20 years in 80 cases (31.5%), and >20 years in 72 cases (28.3%).
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
